---
title: "Bristol Myers’ EVP, Chief Medical Officer Cristian Massacesi disposes of 6,249 common shares worth $403,700.93"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298642486.md"
description: "Bristol-Myers Squibb EVP and Chief Medical Officer Cristian Massacesi sold 6,249 common shares on September 9 at $64.57 per share, totaling approximately $403,700. Following the transaction, he retained 18,748 shares."
datetime: "2026-09-10T20:38:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298642486.md)
  - [en](https://longbridge.com/en/news/298642486.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298642486.md)
generator: "portal-rs"
---

# Bristol Myers’ EVP, Chief Medical Officer Cristian Massacesi disposes of 6,249 common shares worth $403,700.93

-   Bristol-Myers Squibb EVP, Chief Medical Officer, Head of Development Cristian Massacesi sold 6,249 common shares on Sep. 9. \* Sale priced at USD 64.57 per share. \* Massacesi held 18,748 shares following the transaction. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002080176-26-000006), on September 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)

## Related News & Research

- [Bristol Myers Squibb (BMY) Doubles MRD‑Negative CR to 41.1% in Phase 3 EXCALIBER-RRMM](https://longbridge.com/en/news/300139432.md)
- [Bristol Myers Squibb wins FDA accelerated approval for ZENBEXUS combo in multiple myeloma](https://longbridge.com/en/news/300139167.md)
- [Amazon.com, Inc. $AMZN Shares Newly Bought by Glenview Trust Co](https://longbridge.com/en/news/300214023.md)
- [BMS reports positive data from Phase II QUINTESSENTIAL study for r/r MM](https://longbridge.com/en/news/298442546.md)
- [Big AI's content problem: Take the work, keep the money](https://longbridge.com/en/news/300217405.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**